Luke O'Neill

USPTO Granted Patents = 11 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 38(Granted Patents)

Company Filing History:

5 out of 8

Opsona Therapeutics Limited

patents

4 out of 340

The University of Queensland

patents

4 out of 39

The Provost, Fellows, Foundation Scholars, and the Other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin

patents

4. 1 out of 46

The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin

patents

5. 1 out of 1

The Coombe Lying-in Hospital

patent

6. 1 out of 1

The Provost, Fellows, Foundation Scholars, and the and the Other Members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin

patent

where one patent can have more than one assignee

Years Active: 2012-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11858922 - Sulfonylureas and related compounds and use of same (2024-01-02),

2. 11840543 - Compounds and uses (2023-12-12),

3. 11278593 - Composition and methods for the treatment of degenerative retinal conditions (2022-03-22),

4. 11130731 - Sulfonylureas and related compounds and use of same (2021-09-28),

5. 10538487 - Sulfonylureas and related compounds and use of same (2020-01-21),

6. 9234046 - Treatment of renal disease (2016-01-12),

7. 8933011 - Treatment of preterm labor with toll-like receptor 9 antagonists (2015-01-13),

8. 8734788 - Composition and method for treatment of reperfusion injury and tissue damage (2014-05-27),

9. 8580255 - Method for the treatment of rheumatoid arthritis using a TLR2 antagonistic antibody (2013-11-12),

10. 8414887 - Methods for suppressing Toll-like Receptor 4 (TLR4) function using TLR14 antagonists (2013-04-09),

11. 8221992 - Assays for determining compounds which modulate TRAM phosphorylation (2012-07-17),

Title: The Innovations of Luke O'Neill: A Leader in Pharmaceutical Patents

Introduction

Luke O'Neill, an esteemed inventor based in Dublin, Ireland, holds an impressive portfolio of 11 patents. His work primarily focuses on the development of novel compounds aimed at treating various medical disorders, showcasing his significant contribution to pharmaceutical sciences.

Latest Patents

Among his latest innovations are patents such as "Sulfonylureas and Related Compounds and Use of Same." This invention delves into compounds governed by specific chemical formulas, including pharmaceutically acceptable salts, solvates, and prodrugs. It emphasizes at least one nitrogen atom in its structure and addresses disorders mediated by the NLRP3 inflammasome, offering promising methods for treatment and diagnosis. Additionally, the patent encompasses compounds aimed at stimulating insulin secretion, further indicating the dual action of these innovative treatments.

Career Highlights

Luke O'Neill has made significant strides in his career, contributing his expertise to renowned organizations like Opsona Therapeutics Limited and The University of Queensland. His commitment to research and development, particularly in the realm of pharmaceutical innovations, has positioned him as a prominent figure in the field.

Collaborations

Throughout his career, O'Neill has collaborated with notable colleagues, including Rebecca Coll and Matthew Cooper. These partnerships have facilitated the exchange of ideas and expertise, propelling advancements in the discoveries he has made.

Conclusion

In summary, Luke O'Neill's contributions to the field of pharmaceuticals through his innovative patents and collaborative efforts mark him as a leading inventor in the industry. His continuous work in developing compounds that address significant medical challenges ensures his legacy as an influential figure in the realm of health and medicine.

This text is generated by artificial intelligence and may not be accurate.